Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011 / 부인종양

OBJECTIVE: Evaluate the impact of radiotherapy on cause specific survival (CSS) and overall survival (OS) for stage (I-III) clear cell, mucinous, and endometriod ovarian cancer. METHODS: We analyzed incidence, survival, and treatments from the Surveillance, Epidemiology, and End Results (SEER) Program from 2004 to 2011 for clear cell, mucinous, and endometriod histologies of the ovary for stages (I-III). We examined CSS and OS for all three histologies combined and each histology with relation to the use of adjuvant radiation therapy (RT). Survival analysis was calculated by Kaplan-Meier and log-rank analysis. RESULTS: CSS was higher in individuals not receiving RT at 5 years (81% vs. 74%) and 10 years (74% vs. 65%, p=0.003). OS was higher in individuals not receiving RT at 5 years (76% vs. 73%) and 10 years (64% vs. 59%, p=0.039). Stage III patients receiving RT had a higher OS at 5 years (54% vs. 44%) and 10 year intervals (36% vs. 30%, p=0.037). Stage III patients with mucinous histology receiving RT had a higher OS at 5 years (50% vs. 36%) and 10 years (45% vs. 26%, p=0.052). CONCLUSION: Those receiving RT had a lower CSS and OS at 5 and 10 years. However, subgroup analysis revealed a benefit of RT in terms of OS for all stage III patients and for stage III patients with mucinous histology.

Survival rates and prognosis of gastric cancer using an actuarial life-table method.

BACKGROUND AND AIMS: The aim of this study was to calculate survival rates and analyze patterns of survival in gastric cancer. METHODS: A total number of 746 patients with gastric cancer registered in the Cancer Registry Center of Research Center of Gastroenterology and Liver Disease of Shahid Beheshti University of Medical Sciences, Iran, from Dec 21, 2001 to Dec 21, 2006 were investigated. 1- to 5-year survival rates were estimated using life-table method and compared by Wilcoxon (Gehan) test. P<0.05 was considered as statistically significant. All calculations were carried out with SPSS (version 13.0) statistical software. RESULTS: There were 530 male patients with a mean age of 60.5+/-12.6 years and 216 females with a mean age of 57.5+/-13.5 years. Of the total, 454 died and 285 were censored during the investigation. The median survival time was 24.2 months and survival rates at one, two, third, fourth and five years after diagnosis were 73.6, 50.2, 40.6, 33.2 and 29.7%, respectively. Stages of tumor, histology grade, histologic type of cancer, tumor size, age at diagnosis and surgery approach were independent prognostic factors . However, variables such as sex (P=.533), body mass index (P=.214), ethnicity (P=.092), and level of education (P=.762) did not shown significant effects on survival. CONCLUSION: Early detection of patients at lower age and with primary stages and grades of tumor is important to increase patient's life expectancy.

Carcinoma broncoalveolar: sobrevida a cinco años / Bronchioalveolar carcinoma: five year survival

The epidemiology and prognosis of bronchioalveolar carcinoma (BAC) is different from adenocarcinoma. We studied 28 patients who underwent surgical resection and in whom a final histologic diagnosis of bronchioalveolar carcinoma was made. Sixty one percent of patients were asymptomatic at the time of diagnosis. The most usual radiological presentations were pulmonary nodule (11), pulmonary mass (6) and diffuse infiltrate (6). Nine patients (9/25) were never smokers. Bronchoscopy provided the diagnosis only in 4/26 patients. Patients were classified as stage IA 11/24, IB 5/24 IIIB in 2/24 and IV in 6/24. Five-year survival for the entire group was 65%. Patients with focal lesions had a longer survival. The survival in patients who underwent potentially curative resections was 62.8 +/- 44.0 months. When surgery was considered non-curative, survival was 21.2 +/- 19.5 months (p = 0.0064). Five-year survival in stage IA patients was 80%. Survival of patients with non-mucinous histology was longer than those with mucinous type carcinomas (54.9 +/- 25.0 months vs. 5.33 +/- 4.04, p < 0.0001) but the 5-year-survival was not statistically different. In conclusion, BAC has a favourable prognosis. The best survival rate was found in focal forms, represented by early tumor, nodes, metastasis (TNM) stages and non-mucinous BAC among the histological groups.

Predictors of surgery outcome for colorectal carcinoma in the United Arab Emirates

In this retrospective study, 72 patients with colorectal cancer were followed up for a mean period of 28.2 months. Predictors of recurrence and survival were determined using standard analyses. Univariate analyses identified a group of patients with a shorter time to recurrence. The mean overall survival time was 63.2 +/- 7.7 months and survival time was shorter for younger patients with palliative resection, lymph node metastasis and peritoneal nodules. In multivariate Cox proportional hazards analysis, the hazard ratio for positive lymph nodes was 2.54 [95% CI: 1.36-4.79] compared to negative nodes, and for Dukes' stages A and B compared to stage C it was 0.45 [95% CI: 0.25-0.81]